Amylyx Announces Withdrawal of ALS Drug Relyvrio and Workforce Reduction
TL;DR Summary
Amylyx Pharmaceuticals has announced the withdrawal of its A.L.S. drug, Relyvrio, from the market in the United States and Canada after a large clinical trial found that the treatment did not work any better than a placebo. The drug, approved by the FDA in 2022, was one of the few treatments available for A.L.S., a severe neurological disorder. Patients currently taking the medication can transition to a free drug program, while new patients will no longer be able to start the treatment.
- A.L.S. Drug Relyvrio Will Be Taken Off the Market, Its Maker Says The New York Times
- Amylyx to Pull ALS Drug From Market After Failed Trial Bloomberg
- Amylyx Is Cutting 70% of Its Workforce and Pulling ALS Drug From the Market Barron's
- Amylyx to pull ALS drug from market, cut 70% of staff STAT
- Cambridge firm Amylyx will pull ALS drug from market, lay off staff The Boston Globe
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
80%
408 → 82 words
Want the full story? Read the original article
Read on The New York Times